Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion

Yi Luo, MD PhD, Lijian Shao, MD PhD, Jianhui Chang, MS, Wei Feng, MD, Chengcheng Li, PhDcandidate, Y. Lucy Liu, MD PhD, Michele Cottler-Fox, MD, Peter D Emanuel, MD, Peter Murray, PhD, Daohong Zhou, MD

Blood (2014) 124 (21): 2909.

https://doi.org/10.1182/blood.V124.21.2909.2909

Published: 2014

Journal Articles

Advanced Osteolytic Lesions (OL), Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM)

Mariam M Boota, MD, Rashid Z Khan, MD, Eric R Rosenbaum, MD MPH, Ahmed Abuabdou, MD, Chris W Williams, Bart Barlogie, MD PhD, Michele Cottler-Fox, MD

Blood (2014) 124 (21): 3858.

https://doi.org/10.1182/blood.V124.21.3858.3858

Published: 2014

Journal Articles

Risk Of Myelodysplastic Syndrome (MDS) After Hematopoietic Progenitor Cell Collection Using Plerixafor

Rashid Z Khan, MD, Eric R Rosenbaum, MD, MPH, Mariam M Boota, Saad Z Usmani, MD, FACP, Bart Barlogie, MD, PhD, Michele Cottler-Fox, M.D.

Blood (2013) 122 (21): 4650.

https://doi.org/10.1182/blood.V122.21.4650.4650

Published: 2013

Journal Articles

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood (2013) 121 (23): 4753–4757.

https://doi.org/10.1182/blood-2012-11-466961

Published: 2013

Includes: Supplemental data

Journal Articles

Percent cPRA (calculated Panel Reactive Antibody) Value Predicts Percent Positive Platelet Crossmatches

Soumya Pandey, MD, Eric R Rosenbaum, MD, MPH, Michele Cottler-Fox, MD, Terry O Harville, MD PhD

Blood (2012) 120 (21): 3436.

https://doi.org/10.1182/blood.V120.21.3436.3436

Published: 2012

Journal Articles

Hematopoietic Progenitor Cell (HPC) Collection Is Feasible in Previously Transplanted Multiple Myeloma Patients and Plerixafor Improves Collection

Xenofon Papanikolaou, MD, Lisa Tyler, Bart Barlogie, MD, PhD, Michele Cottler-Fox, MD

Blood (2012) 120 (21): 4127.

https://doi.org/10.1182/blood.V120.21.4127.4127

Published: 2012

Journal Articles

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

Blood (2012) 120 (21): 579.

https://doi.org/10.1182/blood.V120.21.579.579

Published: 2012

Journal Articles

A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients,

Ahmed Y Abuabdou, MD, Eric R Rosenbaum, MD, MPH, Saad Usmani, MD, FACP, Bart Barlogie, MD, Ph.D, Michele Cottler-Fox, MD

Blood (2011) 118 (21): 4051.

https://doi.org/10.1182/blood.V118.21.4051.4051

Published: 2011

Journal Articles

A Successful Model for Predicting CD34+ Cell Collection by Apheresis.

Eric R Rosenbaum, M.D., M.P.H., Bernadette O'Connell, B.S., Michele Cottler-Fox, M.D.

Blood (2010) 116 (21): 1182.

https://doi.org/10.1182/blood.V116.21.1182.1182

Published: 2010

Journal Articles

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Bart Barlogie, Guido Tricot, Jeff Haessler, Frits van Rhee, Michele Cottler-Fox, Elias Anaissie, James Waldron, Mauricio Pineda-Roman, Raymond Thertulien, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, John Crowley, Jeffrey Sawyer

Blood (2008) 111 (1): 94–100.

https://doi.org/10.1182/blood-2007-06-097444

Published: 2008

Journal Articles

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

Blood (2006) 109 (6): 2276–2284.

https://doi.org/10.1182/blood-2006-07-038430

Published: 2006

Journal Articles

Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.

Frederica Cavallo, MD, Vanessa Bolejak, MPH, Michele Cottler-Fox, MD, Antje Hoering, PhD, Frits van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD

Blood (2005) 106 (11): 1981.

https://doi.org/10.1182/blood.V106.11.1981.1981

Published: 2005

Journal Articles

Mobilization of Stem Cells with DT-PACE Plus Pegfilgrastim vs. DT-PACE Plus Filgrastim in Previously Treated MM Patients.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Michael Burns, BS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Michele Cottler-Fox, MD

Blood (2005) 106 (11): 1972.

https://doi.org/10.1182/blood.V106.11.1972.1972

Published: 2005

Journal Articles

Myeloma Cells Cultivate Megakaryocytes To Promote Lytic Bone Disease.

Shmuel Yaccoby, PhD, Rinku Saha, Ewa Kozlowska, Yun Ge, PhD, Wen Ling, Michele Cottler-Fox, MD, Bart Barlogie, MD, PhD, Guido Tricot, MD

Blood (2005) 106 (11): 2495.

https://doi.org/10.1182/blood.V106.11.2495.2495

Published: 2005

Journal Articles

Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).

Jumei Shi, MD, PhD, Guido Tricot, MD, PhD, Susann Szmania, BS, Cristyn Camet, BS, Nancy Rosen, BS, Michele Cottler-Fox, MD, Bart Barlogie, MD, PhD, Dario Campana, MD, PhD, Frits van Rhee, MD, PhD

Blood (2005) 106 (11): 3392.

https://doi.org/10.1182/blood.V106.11.3392.3392

Published: 2005

Journal Articles

Reciprocal Interaction between Megakaryocytes and Myeloma Cells Results in Increased Survival and Proliferation of Myeloma Cells.

Shmuel Yaccoby, PhD, Rinku Saha, Ewa Kozlowska, Yun Ge, PhD, Wen Ling, Michele Cottler-Fox, MD, Bart Barlogie, MD, PhD, Guido Tricot, MD

Blood (2005) 106 (11): 628.

https://doi.org/10.1182/blood.V106.11.628.628

Published: 2005

Journal Articles

KIR-LIGAND Mismatched Natural Killer Cells Effectively Kill Primary Myeloma and Myeloma Cell Lines.

Frits van Rhee, MD, PhD, Susann M. Szmania, BS, JuMei Shi, MD, PhD, Michele Cottler-Fox, MD, Justin W. Dyniewski, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 2449.

https://doi.org/10.1182/blood.V104.11.2449.2449

Published: 2004

Journal Articles

NY-ESO-1 Specific T-Cells Are Spontaneously Present in High-Risk Myeloma and Kill Primary Myeloma Cells.

Frits van Rhee, MD, PhD, Susann M. Szmania, BS, Amberly Moreno, BS, Ramesh Batchu, PhD, Mindy Pomtree, BS, Nancy Rosen, Michele Cottler-Fox, MD, Bart Barlogie, MD, PhD, Guido J. Trico, MD, PhD

Blood (2004) 104 (11): 2454.

https://doi.org/10.1182/blood.V104.11.2454.2454

Published: 2004

Journal Articles

A Novel Strategy for Combining Immunotherapy with High Dose Chemotherapy and Auto-Transplantation in High Risk Multiple Myeloma.

Susann Szmania, BS, Michele Cottler-Fox, MD, Nancy Rosen, BS, Sanjaya Viswamitra, MD, Amberly Moreno, BS, Mindy Pomtree, BS, Bart Barlogie, MD, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2004) 104 (11): 2920.

https://doi.org/10.1182/blood.V104.11.2920.2920

Published: 2004

Journal Articles

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Michele Cottler-Fox, MD, David Holley, BA, Linda Whigham, HNC, Julie Stover, BA, Erik Rasmussen, MS, Maurizio Zangari, MD, Guido Tricot, MD, PhD, Barthel Barlogie, MD, PhD

Blood (2004) 104 (11): 2884.

https://doi.org/10.1182/blood.V104.11.2884.2884

Published: 2004

NARROW

Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion

Advanced Osteolytic Lesions (OL), Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM)

Risk Of Myelodysplastic Syndrome (MDS) After Hematopoietic Progenitor Cell Collection Using Plerixafor

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Percent cPRA (calculated Panel Reactive Antibody) Value Predicts Percent Positive Platelet Crossmatches

Hematopoietic Progenitor Cell (HPC) Collection Is Feasible in Previously Transplanted Multiple Myeloma Patients and Plerixafor Improves Collection

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients,

A Successful Model for Predicting CD34+ Cell Collection by Apheresis.

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.

Mobilization of Stem Cells with DT-PACE Plus Pegfilgrastim vs. DT-PACE Plus Filgrastim in Previously Treated MM Patients.

Myeloma Cells Cultivate Megakaryocytes To Promote Lytic Bone Disease.

Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).

Reciprocal Interaction between Megakaryocytes and Myeloma Cells Results in Increased Survival and Proliferation of Myeloma Cells.

KIR-LIGAND Mismatched Natural Killer Cells Effectively Kill Primary Myeloma and Myeloma Cell Lines.

NY-ESO-1 Specific T-Cells Are Spontaneously Present in High-Risk Myeloma and Kill Primary Myeloma Cells.

A Novel Strategy for Combining Immunotherapy with High Dose Chemotherapy and Auto-Transplantation in High Risk Multiple Myeloma.

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only